

Table S1. Modeling on risk of CR on ibrutinib

Variable	RR	95% CI	p-value
Age at diagnosis	1.04	0.96-1.11	0.33
Gender			
Male	Referent		
Female	0.93	0.22-3.91	0.92
BMI			
<30	Referent		
≥30	0.50	0.07-3.39	0.48
ECOG PS at diagnosis			
0	Referent		
1	1.50	0.35-6.38	0.58
MZL subtype			
NMZL	Referent		
SMZL	0.42	0.06-2.85	0.37
EMZL	0.56	0.09-3.47	0.53
Stage at diagnosis			
1-2	Referent		
3-4	0.80	0.15-4.17	0.79
B symptoms at diagnosis			
No	Referent		
Yes	2.00	0.56-7.17	0.29
LDH higher than institutional baseline			
No	Referent		
Yes	0.75	0.12-4.71	0.76
BM involvement at diagnosis			
No	Referent		
Yes	2.00	0.28-14.46	0.49

Abbreviations: CR- complete response, BMI- body mass index, PS-performance status, LDH-lactate dehydrogenase

*There were no CR in albumin at diagnosis, monoclonal protein at diagnosis, and complex cytogenetics, hence were not analyzed.